BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33051337)

  • 1. Biomarkers and Strategies for Early Detection of Ovarian Cancer.
    Bast RC; Lu Z; Han CY; Lu KH; Anderson KS; Drescher CW; Skates SJ
    Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2504-2512. PubMed ID: 33051337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Approaches to Ovarian Cancer Screening.
    Nebgen DR; Lu KH; Bast RC
    Curr Oncol Rep; 2019 Jul; 21(8):75. PubMed ID: 31346778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Detection of Ovarian Cancer.
    Elias KM; Guo J; Bast RC
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):903-914. PubMed ID: 30390764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New tumor markers: CA125 and beyond.
    Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
    Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
    Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
    Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early detection of ovarian cancer.
    Badgwell D; Bast RC
    Dis Markers; 2007; 23(5-6):397-410. PubMed ID: 18057523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
    Yang WL; Lu Z; Guo J; Fellman BM; Ning J; Lu KH; Menon U; Kobayashi M; Hanash SM; Celestino J; Skates SJ; Bast RC
    Cancer; 2020 Feb; 126(4):725-736. PubMed ID: 31714597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
    Yang WL; Gentry-Maharaj A; Simmons A; Ryan A; Fourkala EO; Lu Z; Baggerly KA; Zhao Y; Lu KH; Bowtell D; Jacobs I; Skates SJ; He WW; Menon U; Bast RC;
    Clin Cancer Res; 2017 Oct; 23(19):5912-5922. PubMed ID: 28637689
    [No Abstract]   [Full Text] [Related]  

  • 9. Ovarian cancer screening.
    van Nagell JR; Gallion HH; Pavlik EJ; DePriest PD
    Cancer; 1995 Nov; 76(10 Suppl):2086-91. PubMed ID: 8635005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
    Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC
    Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.
    Russell MR; Graham C; D'Amato A; Gentry-Maharaj A; Ryan A; Kalsi JK; Ainley C; Whetton AD; Menon U; Jacobs I; Graham RLJ
    Br J Cancer; 2017 Aug; 117(5):666-674. PubMed ID: 28664912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare.
    Bast RC
    Trans Am Clin Climatol Assoc; 2004; 115():233-47; discussion 247-8. PubMed ID: 17060970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.
    Lu KH; Skates S; Hernandez MA; Bedi D; Bevers T; Leeds L; Moore R; Granai C; Harris S; Newland W; Adeyinka O; Geffen J; Deavers MT; Sun CC; Horick N; Fritsche H; Bast RC
    Cancer; 2013 Oct; 119(19):3454-61. PubMed ID: 23983047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
    Fortner RT; Schock H; Le Cornet C; Hüsing A; Vitonis AF; Johnson TS; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Papatesta EM; La Vecchia C; Palli D; Sieri S; Tumino R; Sacerdote C; Mattiello A; Onland-Moret NC; Peeters PH; Bueno-de-Mesquita HBA; Weiderpass E; Quirós JR; Duell EJ; Sánchez MJ; Navarro C; Ardanaz E; Larrañaga N; Nodin B; Jirström K; Idahl A; Lundin E; Khaw KT; Travis RC; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Terry KL; Cramer DW; Kaaks R
    Int J Cancer; 2018 Apr; 142(7):1355-1360. PubMed ID: 29159934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer.
    Tcherkassova J; Abramovich C; Moro R; Chen C; Schmit R; Gerber A; Moro R
    Tumour Biol; 2011 Aug; 32(4):831-8. PubMed ID: 21625941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
    Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
    Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
    Lentz SE; Powell CB; Haque R; Armstrong MA; Anderson M; Liu Y; Jiang W; Chillemi G; Shaw S; Alvarado MM; Kushi LH; Skates SJ
    Gynecol Oncol; 2020 Dec; 159(3):804-810. PubMed ID: 33012551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer.
    van Nagell JR; DePriest PD; Reedy MB; Gallion HH; Ueland FR; Pavlik EJ; Kryscio RJ
    Gynecol Oncol; 2000 Jun; 77(3):350-6. PubMed ID: 10831341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial.
    Menon U; Gentry-Maharaj A; Burnell M; Ryan A; Kalsi JK; Singh N; Dawnay A; Fallowfield L; McGuire AJ; Campbell S; Skates SJ; Parmar M; Jacobs IJ
    Health Technol Assess; 2023 May; ():1-81. PubMed ID: 37183782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Program for early detection of ovarian cancer for women as prophylaxis provided at a municipal hospital].
    Cnota W; Sodowski K; Olesiak-Andryszczak M; Pilch-Kowalczyk M
    Wiad Lek; 2004; 57 Suppl 1():43-7. PubMed ID: 15884203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.